SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.62 CNY | -1.05% |
|
+2.25% | -5.63% |
| Sales 2024 * | 44.43B 6.13B | Sales 2025 * | 50.5B 6.97B | Capitalization | 57.14B 7.89B |
|---|---|---|---|---|---|
| Net income 2024 * | 3.24B 448M | Net income 2025 * | 4.12B 569M | EV / Sales 2024 * | 1.63 x |
| Net Debt 2024 * | 15.46B 2.13B | Net Debt 2025 * | 17.72B 2.45B | EV / Sales 2025 * | 1.48 x |
| P/E ratio 2024 * |
19.3
x | P/E ratio 2025 * |
15.1
x | Employees | 40,370 |
| Yield 2024 * |
1.59% | Yield 2025 * |
2.04% | Free-Float | 63.46% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -1.05% | ||
| 1 week | +2.25% | ||
| Current month | +1.94% | ||
| 1 month | -0.21% | ||
| 3 months | -6.12% | ||
| 6 months | -12.84% | ||
| Current year | -5.63% |
1 week
23.11
24.26
1 month
22.9524.62
Current year
20.3825.89
1 year
20.3832.08
3 years
20.3891.69
5 years
20.3891.69
10 years
16.5091.69
| Managers | Title | Age | Since |
|---|---|---|---|
De Yong Wen
CEO | Chief Executive Officer | 52 | - |
Dong Ming Li
PSD | President | 55 | 20-10-28 |
Yi Fang Wu
CHM | Chairman | 54 | 04-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Fang Yao
BRD | Director/Board Member | 54 | 10-04-08 |
Qi Yu Chen
BRD | Director/Board Member | 52 | 94-03-31 |
Xiao Hui Guan
BRD | Director/Board Member | 53 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.27% | 2 M€ | -17.28% | - | |
| 1.18% | 4 M€ | -2.96% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-05 | 23.62 | -1.05% | 11 217 380 |
| 24-06-05 | 23.87 | +0.08% | 18,244,010 |
| 24-06-04 | 23.85 | +2.01% | 17,467,340 |
| 24-06-03 | 23.38 | +0.91% | 12,906,830 |
| 24-05-31 | 23.17 | +0.09% | 6,103,400 |
End-of-day quote Shanghai S.E., June 05, 2024
More quotes
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a pharmaceutical group organized around 4 areas of activities:
- research, development and manufacturing of medicines (72.1% of net sales): for the treatment of cardiovascular diseases, digestive tract, metabolism, central nervous system and blood system disorders, and infectious diseases;
- sale of medical equipments and diagnosis products (17.3%);
- medical and hospital services (10.5%);
- other (0.1%).
China accounts for 72.9% of net sales.
Sector
Pharmaceuticals
Calendar
2024-06-26
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
23.87
CNY
Average target price
28.61
CNY
Spread / Average Target
+19.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.63% | 7.95B | |
| +43.45% | 749B | |
| +39.42% | 605B | |
| -6.60% | 351B | |
| +19.01% | 328B | |
| +8.07% | 292B | |
| +11.92% | 216B | |
| -2.62% | 214B | |
| +0.24% | 167B | |
| +6.39% | 165B |
- Stock Market
- Equities
- 600196 Stock
